H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $13.75 average price target.
See today’s analyst top recommended stocks >>
Based on Pluristem’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $23K and GAAP net loss of $6.37 million. In comparison, last year the company earned revenue of $50K and had a GAAP net loss of $8.68 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Read More on PSTI: